TiGenix NV | CIK:0001581987 | 3

  • Filed: 5/11/2018
  • Entity registrant name: TiGenix NV (CIK: 0001581987)
  • Generator: Merrill
  • SEC filing page: http://www.sec.gov/Archives/edgar/data/1581987/000110465918032350/0001104659-18-032350-index.htm
  • XBRL Instance: http://www.sec.gov/Archives/edgar/data/1581987/000110465918032350/tig-20171231.xml
  • XBRL Cloud Viewer: Click to open XBRL Cloud Viewer
  • EDGAR Dashboard: https://edgardashboard.xbrlcloud.com/edgar-dashboard/?cik=0001581987
  • Open this page in separate window: Click
  • ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory

     

    25. Segment information

     

    The Group’s activities are managed and operated in one segment, biopharmaceuticals. There is no other significant class of business, either individual or in aggregate. As such, the chief operating decision maker (i.e., the CEO) reviews the operating results and operating plans and makes resource allocation decisions on a company-wide basis.

     

    Geographical information

     

    Revenue of 2017 from continuing operations are mainly related to grants and other operating income 0.6 million euros Spain and 0.3 million euros Belgium.

     

    The Group’s non-current assets by location are presented below:

     

     

     

    As at December 31,

     

    Thousands of euros

     

    2017

     

    2016

     

    2015

     

    Belgium

     

    142

     

    154

     

    2,159

     

    Spain

     

    42,282

     

    51,927

     

    52,082

     

     

     

     

     

     

     

     

     

    Total

     

    42,424

     

    52,081

     

    54,241